Nucleotide binding is the critical regulator of ABCG2 conformational transitions
Zsuzsanna Gyöngy,
Gábor Mocsár,
Éva Hegedűs,
Thomas Stockner,
Zsuzsanna Ritter,
László Homolya,
Anita Schamberger,
Tamás I Orbán,
Judit Remenyik,
Gergely Szakacs,
Katalin Goda
Affiliations
Zsuzsanna Gyöngy
Department of Biophysics and Cell Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary; Doctoral School of Molecular Cell and Immune Biology, University of Debrecen, Debrecen, Hungary
Gábor Mocsár
Department of Biophysics and Cell Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
Éva Hegedűs
Department of Biophysics and Cell Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
Institute of Pharmacology, Center for Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria
Zsuzsanna Ritter
Department of Biophysics and Cell Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary; Doctoral School of Molecular Cell and Immune Biology, University of Debrecen, Debrecen, Hungary
László Homolya
Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary
Anita Schamberger
Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary
Tamás I Orbán
Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary
Judit Remenyik
Institute of Food Technology, Faculty of Agricultural and Food Sciences and Environmental Management, University of Debrecen, Debrecen, Hungary
Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary; Institute of Cancer Research, Medical University of Vienna, Vienna, Austria
ABCG2 is an exporter-type ABC protein that can expel numerous chemically unrelated xeno- and endobiotics from cells. When expressed in tumor cells or tumor stem cells, ABCG2 confers multidrug resistance, contributing to the failure of chemotherapy. Molecular details orchestrating substrate translocation and ATP hydrolysis remain elusive. Here, we present methods to concomitantly investigate substrate and nucleotide binding by ABCG2 in cells. Using the conformation-sensitive antibody 5D3, we show that the switch from the inward-facing (IF) to the outward-facing (OF) conformation of ABCG2 is induced by nucleotide binding. IF-OF transition is facilitated by substrates, and hindered by the inhibitor Ko143. Direct measurements of 5D3 and substrate binding to ABCG2 indicate that the high-to-low affinity switch of the drug binding site coincides with the transition from the IF to the OF conformation. Low substrate binding persists in the post-hydrolysis state, supporting that dissociation of the ATP hydrolysis products is required to reset the high substrate affinity IF conformation of ABCG2.